ADC Therapeutics has culled its clinical asset ADCT-602 while announcing more data on its flagship drug Zynlonta ...

Q1 2025 Management View CEO Ameet Mallik reported that "the first quarter of 2025 represented a solid period of continued performance for our company," highlighting total first quarter revenues of $23 ...

Zynlonta manufacturer ADC Therapeutics is continuing to prune its pipeline, calling time on its sole clinical-stage candidate ...

Q1 2025 Earnings Call Transcript May 14, 2025 ADC Therapeutics SA beats earnings expectations. Reported EPS is $-0.36, ...

ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...

LOTIS-7 abstract accepted for presentation at the European Hematology Association 2025 Congress (EHA2025) and the 18 th International Conference on Malignant Lymphoma (ICML); ZYNLONTA® plus ...

Items affecting comparability (IAC). * The strategic portfolio includes Sobi's medicines Altuvoct, Aspaveli/Empaveli, Doptelet, Gamifant, Vonjo and Zynlonta, and royalty on Sanofi's sales of ...

The trial evaluated the combination of ZYNLONTA and glofitamab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). An overall response rate (ORR) of 95.5% and a complete ...

ADC Therapeutics has culled its clinical asset ADCT-602 while announcing more data on its flagship drug Zynlonta (loncastuximab tesirine-lpyl). Following the two announcements, the company’s ...

CFO Pepe Carmona stated, "ZYNLONTA net product revenues in the first quarter of 2025 were $17.4 million as compared to $17.8 million in the same quarter of 2024." He reported total operating ...

LOTIS-7 abstract accepted for presentation at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma ...